COMP <GO>
BMRN vs UNH // FREE CASH FLOW YIELD
BioMarin Pharmaceutical Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BMRN 8
— UNH 7
▲ FREE CASH FLOW YIELD LEADER: BMRN
LAST: $58.51 (+1.77%) • MKT CAP: $11.13B
fcf-yield
6.51%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 88.57% | -10.87 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 11.47% | -5.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 16.4x | +4.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 6.51% | 6.48% | +0.03 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | 4.82% | +7.88 | BMRN | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 3.14% | +7.66 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 6.46% | +6.44 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 3.12 | +2.45 | BMRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.74% | -0.04 | BMRN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 56.0 | -1.53 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.33 | +0.62 | BMRN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 17.1x | +9.71 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $364.66B | -$353.53B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | UNH REV | BMRN GROSS % | UNH GROSS % | BMRN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $447.57B | 77.7% | 88.7% | $725.0M | $16.07B |
| FY 2024 | $2.85B | $400.28B | 79.7% | 88.3% | $487.4M | $20.70B |
| FY 2023 | $2.42B | $371.62B | 44.0% | 89.6% | $50.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
UNH // BETA 0.33